Home / Health / Scientists Rewrite APOE4, Slashing Alzheimer's Risk

Scientists Rewrite APOE4, Slashing Alzheimer's Risk

Summary

  • New gene therapy converts high-risk APOE4 to lower-risk APOE3.
  • The process demonstrated minimal impact on surrounding DNA.
  • Human trials for this gene therapy are estimated in 5-10 years.

Researchers at the University of Bristol have achieved a significant breakthrough in potentially combating Alzheimer's disease by developing a gene therapy to convert the APOE4 gene into the less risky APOE3 variant. This advancement targets a primary genetic predictor of the condition.

The study successfully demonstrated in human immune cells that the APOE4 gene can be edited into APOE3 with minimal unintended alterations to nearby DNA. This addresses a key safety concern that has previously hindered gene editing research for neurological diseases.

This experimental therapy utilizes engineered enzymes to make precise chemical changes to DNA. The team plans to package this editing machinery into a modified virus for potential bloodstream injection, aiming to deliver the therapeutic changes to the brain.

While the initial results are promising, the therapy is still in its early stages. The researchers estimate that human testing could commence in five to ten years, pending rigorous safety evaluations and further development of the delivery system.

Despite the significant potential, experts caution that genetics are not destiny, and lifestyle factors also play a role in Alzheimer's risk. Nevertheless, this gene therapy offers a hopeful new avenue for treating individuals with the APOE4 gene.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.

Read more news on

Property Code: 5571